Skip to main content
Top
Published in: Breast Cancer Research and Treatment 1/2012

01-01-2012 | Erratum

Erratum to: HER2 Ile655Val polymorphism contributes to breast cancer risk: evidence from 27 case–control studies

Authors: Su Lu, Zhanwei Wang, Hong Liu, Xishan Hao

Published in: Breast Cancer Research and Treatment | Issue 1/2012

Login to get access

Excerpt

Authors would like to add the following Acknowledgements: …
Metadata
Title
Erratum to: HER2 Ile655Val polymorphism contributes to breast cancer risk: evidence from 27 case–control studies
Authors
Su Lu
Zhanwei Wang
Hong Liu
Xishan Hao
Publication date
01-01-2012
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2012
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-010-1196-1

Other articles of this Issue 1/2012

Breast Cancer Research and Treatment 1/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine